(PFE) Pfizer - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7170811035
Medicines, Vaccines, Biosimilars, Injectables, Anti-Infectives
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 8.75% |
| Yield on Cost 5y | 5.99% |
| Yield CAGR 5y | 2.47% |
| Payout Consistency | 97.9% |
| Payout Ratio | 53.8% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 24.0% |
| Value at Risk 5%th | 37.2% |
| Relative Tail Risk | -5.71% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.19 |
| Alpha | -1.76 |
| CAGR/Max DD | -0.25 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.381 |
| Beta | 0.476 |
| Beta Downside | 0.526 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.59% |
| Mean DD | 29.04% |
| Median DD | 32.74% |
Description: PFE Pfizer December 02, 2025
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes a broad portfolio of medicines and vaccines across therapeutic areas such as cardiovascular, migraine, infectious disease, oncology, immunology and rare diseases. Its flagship brands include Eliquis, Prevnar, Comirnaty, Paxlovid and a growing line of biosimilars and specialty drugs, and the firm also operates a contract-manufacturing business serving hospitals, pharmacies and government agencies worldwide.
Key recent metrics: FY 2023 revenue reached $100.3 billion, up ≈ 3 % YoY, while diluted EPS was $3.73 and the company paid a dividend yielding roughly 4.1 %. R&D spending remained high at about $13 billion, reflecting continued investment in mRNA platforms, oncology pipelines (e.g., Ibrance, Tivdak) and biosimilar expansion. The sector’s growth is driven by an aging population, rising chronic-disease prevalence and sustained U.S. healthcare expenditure, but pricing pressure and patent cliffs remain material headwinds.
For a deeper, data-driven valuation framework, you may find ValueRay’s analyst tools worth a look.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 9.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.22 > 1.0 |
| NWC/Revenue: 16.45% < 20% (prev 0.02%; Δ 16.43% < -1%) |
| CFO/TA 0.06 > 3% & CFO 13.08b > Net Income 9.82b |
| Net Debt (60.37b) to EBITDA (21.17b): 2.85 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.71b) vs 12m ago 0.16% < -2% |
| Gross Margin: 71.19% > 18% (prev 0.59%; Δ 7060 % > 0.5%) |
| Asset Turnover: 29.32% > 50% (prev 27.54%; Δ 1.79% > 0%) |
| Interest Coverage Ratio: 5.36 > 6 (EBITDA TTM 21.17b / Interest Expense TTM 2.70b) |
Altman Z'' 3.70
| A: 0.05 (Total Current Assets 46.92b - Total Current Liabilities 36.60b) / Total Assets 208.73b |
| B: 0.58 (Retained Earnings 121.15b / Total Assets 208.73b) |
| C: 0.07 (EBIT TTM 14.47b / Avg Total Assets 214.10b) |
| D: 0.98 (Book Value of Equity 113.56b / Total Liabilities 115.64b) |
| Altman-Z'' Score: 3.70 = AA |
Beneish M -3.39
| DSRI: 0.78 (Receivables 14.26b/17.69b, Revenue 62.78b/60.43b) |
| GMI: 0.82 (GM 71.19% / 58.73%) |
| AQI: 0.95 (AQ_t 0.68 / AQ_t-1 0.72) |
| SGI: 1.04 (Revenue 62.78b / 60.43b) |
| TATA: -0.02 (NI 9.82b - CFO 13.08b) / TA 208.73b) |
| Beneish M-Score: -3.39 = AA |
ValueRay F-Score (Strict, 0-100) 54.33
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: 5.00% |
| 3. FCF Margin: 16.53% |
| 4. Debt/Equity: 0.66 |
| 5. Debt/Ebitda: 2.85 |
| 6. ROIC - WACC: 1.89% |
| 7. RoE: 10.91% |
| 8. Revenue Trend: -68.94% |
| 9. EPS Trend: -42.60% |
What is the price of PFE shares?
As of January 24, 2026, the stock is trading at USD 25.65 with a total of 45,360,711 shares traded.
Over the past week, the price has changed by +1.68%, over one month by +4.82%, over three months by +7.58% and over the past year by +5.77%.
Over the past week, the price has changed by +1.68%, over one month by +4.82%, over three months by +7.58% and over the past year by +5.77%.
Is PFE a buy, sell or hold?
Pfizer has received a consensus analysts rating of 3.56.
Therefor, it is recommend to hold PFE.
- Strong Buy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.7 | 11.7% |
| Analysts Target Price | 28.7 | 11.7% |
| ValueRay Target Price | 27.3 | 6.4% |
PFE Fundamental Data Overview January 17, 2026
P/E Trailing = 15.0523
P/E Forward = 8.7489
P/S = 2.3446
P/B = 1.5862
P/EG = 3.7725
Revenue TTM = 62.78b USD
EBIT TTM = 14.47b USD
EBITDA TTM = 21.17b USD
Long Term Debt = 56.55b USD (from longTermDebt, last quarter)
Short Term Debt = 4.30b USD (from shortTermDebt, last quarter)
Debt = 61.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.37b USD (from netDebt column, last quarter)
Enterprise Value = 207.57b USD (147.20b + Debt 61.71b - CCE 1.34b)
Interest Coverage Ratio = 5.36 (Ebit TTM 14.47b / Interest Expense TTM 2.70b)
EV/FCF = 20.01x (Enterprise Value 207.57b / FCF TTM 10.38b)
FCF Yield = 5.00% (FCF TTM 10.38b / Enterprise Value 207.57b)
FCF Margin = 16.53% (FCF TTM 10.38b / Revenue TTM 62.78b)
Net Margin = 15.64% (Net Income TTM 9.82b / Revenue TTM 62.78b)
Gross Margin = 71.19% ((Revenue TTM 62.78b - Cost of Revenue TTM 18.09b) / Revenue TTM)
Gross Margin QoQ = 74.95% (prev 64.29%)
Tobins Q-Ratio = 0.99 (Enterprise Value 207.57b / Total Assets 208.73b)
Interest Expense / Debt = 1.06% (Interest Expense 652.0m / Debt 61.71b)
Taxrate = 21.0% (US default 21%)
NOPAT = 11.43b (EBIT 14.47b * (1 - 21.00%))
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 92.80b)
Debt / EBITDA = 2.85 (Net Debt 60.37b / EBITDA 21.17b)
Debt / FCF = 5.82 (Net Debt 60.37b / FCF TTM 10.38b)
Total Stockholder Equity = 90.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.59% (Net Income 9.82b / Total Assets 208.73b)
RoE = 10.91% (Net Income TTM 9.82b / Total Stockholder Equity 90.01b)
RoCE = 9.88% (EBIT 14.47b / Capital Employed (Equity 90.01b + L.T.Debt 56.55b))
RoIC = 7.54% (NOPAT 11.43b / Invested Capital 151.69b)
WACC = 5.65% (E(147.20b)/V(208.91b) * Re(7.67%) + D(61.71b)/V(208.91b) * Rd(1.06%) * (1-Tc(0.21)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.59%
[DCF Debug] Terminal Value 83.67% ; FCFF base≈9.52b ; Y1≈7.55b ; Y5≈5.04b
Fair Price DCF = 16.66 (EV 155.10b - Net Debt 60.37b = Equity 94.73b / Shares 5.69b; r=5.90% [WACC]; 5y FCF grow -24.64% → 2.90% )
EPS Correlation: -42.60 | EPS CAGR: -5.60% | SUE: 2.45 | # QB: 9
Revenue Correlation: -68.94 | Revenue CAGR: -9.12% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.74 | Chg30d=-0.034 | Revisions Net=-2 | Analysts=12
EPS next Year (2026-12-31): EPS=2.98 | Chg30d=-0.072 | Revisions Net=-14 | Growth EPS=-4.5% | Growth Revenue=-1.5%
P/E Forward = 8.7489
P/S = 2.3446
P/B = 1.5862
P/EG = 3.7725
Revenue TTM = 62.78b USD
EBIT TTM = 14.47b USD
EBITDA TTM = 21.17b USD
Long Term Debt = 56.55b USD (from longTermDebt, last quarter)
Short Term Debt = 4.30b USD (from shortTermDebt, last quarter)
Debt = 61.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.37b USD (from netDebt column, last quarter)
Enterprise Value = 207.57b USD (147.20b + Debt 61.71b - CCE 1.34b)
Interest Coverage Ratio = 5.36 (Ebit TTM 14.47b / Interest Expense TTM 2.70b)
EV/FCF = 20.01x (Enterprise Value 207.57b / FCF TTM 10.38b)
FCF Yield = 5.00% (FCF TTM 10.38b / Enterprise Value 207.57b)
FCF Margin = 16.53% (FCF TTM 10.38b / Revenue TTM 62.78b)
Net Margin = 15.64% (Net Income TTM 9.82b / Revenue TTM 62.78b)
Gross Margin = 71.19% ((Revenue TTM 62.78b - Cost of Revenue TTM 18.09b) / Revenue TTM)
Gross Margin QoQ = 74.95% (prev 64.29%)
Tobins Q-Ratio = 0.99 (Enterprise Value 207.57b / Total Assets 208.73b)
Interest Expense / Debt = 1.06% (Interest Expense 652.0m / Debt 61.71b)
Taxrate = 21.0% (US default 21%)
NOPAT = 11.43b (EBIT 14.47b * (1 - 21.00%))
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 92.80b)
Debt / EBITDA = 2.85 (Net Debt 60.37b / EBITDA 21.17b)
Debt / FCF = 5.82 (Net Debt 60.37b / FCF TTM 10.38b)
Total Stockholder Equity = 90.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.59% (Net Income 9.82b / Total Assets 208.73b)
RoE = 10.91% (Net Income TTM 9.82b / Total Stockholder Equity 90.01b)
RoCE = 9.88% (EBIT 14.47b / Capital Employed (Equity 90.01b + L.T.Debt 56.55b))
RoIC = 7.54% (NOPAT 11.43b / Invested Capital 151.69b)
WACC = 5.65% (E(147.20b)/V(208.91b) * Re(7.67%) + D(61.71b)/V(208.91b) * Rd(1.06%) * (1-Tc(0.21)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.59%
[DCF Debug] Terminal Value 83.67% ; FCFF base≈9.52b ; Y1≈7.55b ; Y5≈5.04b
Fair Price DCF = 16.66 (EV 155.10b - Net Debt 60.37b = Equity 94.73b / Shares 5.69b; r=5.90% [WACC]; 5y FCF grow -24.64% → 2.90% )
EPS Correlation: -42.60 | EPS CAGR: -5.60% | SUE: 2.45 | # QB: 9
Revenue Correlation: -68.94 | Revenue CAGR: -9.12% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.74 | Chg30d=-0.034 | Revisions Net=-2 | Analysts=12
EPS next Year (2026-12-31): EPS=2.98 | Chg30d=-0.072 | Revisions Net=-14 | Growth EPS=-4.5% | Growth Revenue=-1.5%
Additional Sources for PFE Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle